The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
NCT06819514
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
DRUG:
EXG110 Injection
Sponsor
Guangzhou Jiayin Biotech Ltd